Multibagger Selection: Grok 4's picks
Grok 4 picked CAPR, INOD, SOUN, UCTT, NRIX with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | CAPR | — | 72% | — | — |
| 2 | INOD | — | 75% | — | — |
| 3 | SOUN | — | 68% | — | — |
| 4 | UCTT | — | 65% | — | — |
| 5 | NRIX | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +0.10% | +0.89% | 1.27x | 0 |
| 1 month | -15.75% | -15.87% | 1.28x | 0 |
The model's market view
Small- and mid-cap US equities face a mixed but constructive backdrop for multibagger candidates in late 2026. AI infrastructure, semiconductor subsystems, voice/agentic AI software, and clinical-stage biotechs with near-term binary regulatory events offer the clearest operating inflections and catalyst density. Liquidity remains adequate above $5M average daily dollar volume in the selected cohort; valuation asymmetry is highest where forward growth or approval-driven commercial ramps are not yet fully priced. Broader small-cap earnings growth is accelerating relative to large caps, supporting multiple expansion if execution holds.
Why each pick
CAPR
Clinical-stage cell therapy company focused on Duchenne muscular dystrophy with a clear binary regulatory catalyst. Cash runway and institutional ownership support survival through the decision window; upside asymmetry exists if the refined upper-limb indication is approved and commercialized.
INOD
AI data engineering and model-evaluation specialist with accelerating revenue, expanding margins, and diversification away from single-customer concentration. Raised full-year growth guidance and new large hyperscaler engagements provide visible catalysts.
SOUN
Voice and agentic AI platform company with accelerating enterprise adoption, sequential margin improvement, and raised full-year revenue outlook. OASYS platform and vertical traction provide operating leverage.
UCTT
Supplier of critical semiconductor subsystems and cleaning services positioned to benefit from AI-driven wafer fab equipment demand. Sequential guidance strength and analyst target upside support the thesis.
NRIX
Clinical-stage biotechnology company with a diversified protein-degradation pipeline and multiple 2026 data catalysts. Strong cash position relative to market capitalization reduces near-term financing pressure.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Opus 5 | ICHR, RUM, OUST, USAR, EMAT |
| Muse Spark 1.1 | CPRX, CLBT, INDP, LOB, PSO |
| Gemini 2.5 Pro | RCAT, LUNR, POET, OKLO, HIMS |
| GPT-6 | ARRY, TSSI, RCAT, INDI, ACMR |
| DeepSeek V3 | RZLV, FEIM, UMAC, QUBT, LRMR |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.